Tidd-Johnson Atiyah, Sebastian Sneha Annie, Co Edzel Lorraine, Afaq Munaza, Kochhar Hansini, Sheikh Mona, Mago Arpit, Poudel Sujan, Fernandez John A, Rodriguez Ivan D, Razdan Sanjay
Division of Research & Academic Affairs, Larkin Community Hospital, South Miami, FL, USA.
Department of Medicine, American University of Antigua College of Medicine, Coolidge, Antigua.
Curr Urol. 2022 Dec;16(4):197-206. doi: 10.1097/CU9.0000000000000145. Epub 2022 Aug 31.
Prostate cancer (PCa) screening remains one of the most controversial topics in clinical and public health. Despite being the second most common cancer in men worldwide, recommendations for screening using prostate-specific antigen (PSA) are unclear. Early detection and the resulting postscreening treatment lead to overdiagnosis and overtreatment of otherwise indolent cases. In addition, several unwanted harms are associated with PCa screening process. This literature review focuses on the limitations of PSA-specific PCa screening, reasons behind the screening controversy, and the novel biomarkers and advanced innovative methodologies that improve the limitations of traditional screening using PSA. With the verdict of whether or not to screen not yet unanimous, we hope to aid in resolution of the long-standing debate.
前列腺癌（PCa）筛查仍是临床和公共卫生领域最具争议的话题之一。尽管前列腺癌是全球男性中第二常见的癌症，但关于使用前列腺特异性抗原（PSA）进行筛查的建议并不明确。早期检测以及由此产生的筛查后治疗导致对原本惰性病例的过度诊断和过度治疗。此外，前列腺癌筛查过程还存在一些不良危害。这篇文献综述聚焦于PSA特异性前列腺癌筛查的局限性、筛查争议背后的原因，以及改善传统PSA筛查局限性的新型生物标志物和先进创新方法。鉴于是否进行筛查尚无定论，我们希望有助于解决这一长期存在的争论。
